Company / Gross Profit
Bio-Rad Laboratories Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$1.3B
FY2025
5-year range
$1.3B / $1.6B
FY2021-FY2025
Trend
-2.8%
vs FY2024
Sector context
#34 of 100
Health Care
What the data says
At $1.3B, Bio-Rad Laboratories's gross profit ranks #34 of 100 in the Health Care sector. Gross Profit has declined for 4 consecutive years, from $1.6B in FY2021 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +1.8%.
Declined from $1.4B to $1.3B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -5.1%
- 5-Year CAGR
- +1.8%
- 10-Year CAGR
- -
Sector benchmark
#34 of 100 in Health CareTop 34% of 100This company $1.3B Sector average $1.8B
▼
-26.3% below sector average
Key checks
Key Insights
- Bio-Rad Laboratories's gross profit has declined for 4 consecutive years.
- 5-year CAGR of +1.8%, indicating consistent growth.
- In FY2025, gross profit decreased 2.8% year-over-year.
- Ranks #34 out of 100 companies in the Health Care sector.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | -2.8% |
| FY2024 | $1.4B | -3.4% |
| FY2023 | $1.4B | -9.0% |
| FY2022 | $1.6B | -4.3% |
| FY2021 | $1.6B | +33.9% |
| FY2020 | $1.2B | -2.7% |
| FY2019 | $1.3B | +10.4% |
| FY2018 | $1.1B | +1.5% |
| FY2017 | $1.1B | -4.8% |
| FY2016 | $1.2B | +5.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026